Table 3 Correlation of DNMT3A expression with clinical characteristics in BCP-ALL

Age

  < 1 or ≥ 10

1(4.5)

6 (7.5)

1.000

 1 ~ 10

21(95.5)

74 (92.5)

Gender

 Male

16 (72.7)

48 (60)

0.327

 Female

6 (27.3)

32 (40)

WBC(*10⁹/L)

  < 50

15 (68.2)

68 (85)

0.118

  ≥ 50

7 (31.8)

12 (15)

Fusion gene

 Negative

19 (86.4)

49 (61.25)

0.264

 ETV6-RUNX1

3 (13.6)

25 (31.25)

 TCF3-PBX1

0 (0)

3 (3.75)

 BCR-ABL1

0 (0)

2 (2.5)

 FUS-ERG

0 (0)

1 (1.25)

MRD at d33

  < 10^–3

18(85.7)

67 (89.3)

0.701

  ≥ 10^–3

3(14.3)

8(10.7)

MRD at d78

  < 10^–4

21 (100)

72 (96)

1.000

  ≥ 10^–4

0(0)

3(4)

Risk classification

 Standard risk

6 (27.3)

16 (20)

0.708

 Intermediate risk

15 (68.2)

58 (72.5)

 High risk

1 (4.5)

6 (7.5)